directory

Ionis Pharmaceuticals, Inc. | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Company Directory for Ionis Pharmaceuticals, Inc.

Team Bitscale

14 Mar 2026 — 1 min read

Ionis Pharmaceuticals, Inc.

Overview

Founded in 1989 and based in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biotechnology leader specializing in RNA-targeted therapeutics, with a major focus on antisense oligonucleotides (ASOs) for treating serious diseases such as neurology and cardiology disorders. Initially named Isis Pharmaceuticals, Ionis achieved industry milestones, including the FDA's approval of Vitravene in 1998—the first antisense drug—and the development of SPINRAZA, which transformed spinal muscular atrophy from a fatal disease into a manageable condition.

Ionis's proprietary ASO technology leverages RNA modulation to control gene expression, resulting in substantial advances in ASO chemistry and a robust pipeline of investigational RNA-targeted medicines. Operating under a fully integrated model, the company independently launches products while forging strategic partnerships with organizations like Biogen and AstraZeneca for late-stage development and commercialization. This approach accelerates market access and maximizes the impact of their innovative therapies.

Basic Information

Industry	research
Founded	1989
Revenue	944M
Headquarters	2855 Gazelle Court, Carlsbad, CA 92010, United States
Languages	English

Contact Details

Phone: +1 760-931-9200
Website: ionis.com
LinkedIn: linkedin.com/company/ionis-pharmaceuticals

Key Focus Areas & Initiatives

Antisense drug discovery
RNA-targeted medicines & therapeutics
Biotechnology research and development
Drug development and clinical trials
Gene expression modulation
Genetic therapies and gene editing
Rare disease treatments
Biopharmaceutical innovation
Partnerships with Biogen and AstraZeneca
Investigation of medicines for serious diseases
Neurology and cardiology drug development
Patient advocacy and support programs
Therapeutic pipeline advancements
Corporate responsibility and community impact
FDA drug approval and orphan drug designation
Disease biology and therapeutic strategies
Market access and commercialization
Healthcare solutions
Lifesaving therapies
Environmental and sustainability initiatives

Technologies Used

Affiliated Organizations & Regional Branches

Akcea Therapeutics, Inc.

Read more

GTM Strategy: The Complete Guide (Framework, Examples & B2B Playbook)

GTM Strategy: The Complete Guide (Framework, Examples & B2B Playbook)

Most things labeled a “GTM strategy” are really a channel checklist wearing a nice slide template. They are activity plans, not a coherent answer to how the business will create, capture, and deliver value for a specific buyer in a specific market. This is written for B2B founders, product marketers,

How Scrut.io Built a Compliance-Signal GTM Machine with Bitscale

Scrut Automation simplifies continuous compliance for cloud-native companies, helping them achieve ISO 27001, SOC 2, PCI DSS, and GDPR compliance 5x faster — with real-time risk monitoring and automated evidence collection.

Clay API Limits, Authentication & Rate Limits Explained

Clay API Limits, Authentication & Rate Limits Explained

Your enrichment workflow ran perfectly on 50 test records. Then you pointed it at 10,000 contacts and everything collapsed: 429 errors, duplicate CRM writes, and a credit balance that evaporated overnight. The Clay API usually is not the root cause. The root cause is treating authentication, rate limits, and

GTM Data Stack for US Outbound Teams

GTM Data Stack for US Outbound Teams

Outbound has changed. Spray-and-pray cadences that worked five years ago now burn through contact lists, damage sender reputation, and leave revenue teams short on pipeline. What separates high-performing US outbound teams in 2026 is not effort or headcount. It is the quality, governance, and architecture of the GTM Data Stack.